We are sorry to announce that we will be closing this Facebook page shortly. It is not a decision we have taken lightly, and we want to be upfront and honest about why we feel it’s necessary.
As a UK pharmaceutical company, we – quite rightly – comply with strict rules, particularly in relation to communications with members of the public. These rules mean that whenever a post on this page mentions a specific drug by name, or talks about the efficacy of a particular treatment is (or its side effects), we have to ask for it to be changed, or pull it. Since the page was launched nearly 18 months ago, we have found ourselves removing a larger and larger proportion of posts, stifling worthwhile discussions.
This page was created - in a spirit of innovation - as a space for people affected by psoriasis to share experiences and information, and to discuss psoriasis and related topics. Janssen is proud to have provided this forum at a time when they weren't as widespread as they are today. But instead of our original intention of facilitating meaningful conversations, our experience shows we are actually hampering conversations that could take place freely on a page run by a patient organisation.
a
We remain committed to providing balanced information and resources on our Psoriasis 360 web site and Psoriasis 360 YouTube channel and we’d be delighted if you would like to connect with us on Twitter. However, from today, we would like to recommend an alternative to this page. We consulted The Psoriasis Association and agreed that their Facebook page would be a great place for your conversations to continue.
Ver
Janssen to remove its Psoriasis 360 Facebook page
All firms have been forced to make commenting available on their Facebook sites since August last year, although they are allowed to change or remove comments once they have been made.
Janssen markets its Stelara drug as a treatment option for adults with moderate to severe plaque psoriasis, and was using the site as a disease awareness campaign for the disease.
Más
No hay comentarios:
Publicar un comentario